



**Dated: May 07, 2025**

To,  
National Stock Exchange of India Limited  
BSE Limited  
Symbol: NSE: GRANULES; BSE: 532482

Sub: Press Release

Dear Sir,  
We are herewith enclosing the press release given by the Company.  
This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours sincerely,

**For GRANULES INDIA LIMITED**

**CHAITANYA TUMMALA  
(COMPANY SECRETARY &  
COMPLIANCE OFFICER)  
Encl. as above**

**REGISTERED OFFICE**

---

Granules India Limited  
CIN: L24110TG1991PLC012471  
15<sup>th</sup> Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad – 500084, Telangana, India  
Contact Us: Tel: +91-40-69043500 |Fax: +91-40-23115145| [mail@granulesindia.com](mailto:mail@granulesindia.com)



## **Press Release**

### **Granules India Earns Gold Rating in First-Ever Corporate-Level EcoVadis Assessment Ranks in the Top 5% Globally Across All Industries**

**Hyderabad, India – May 7, 2025:** Granules India Limited (BSE: 532482, NSE: GRANULES), a vertically integrated pharmaceutical company committed to sustainable and responsible healthcare, has been awarded a **Gold rating by EcoVadis** in its inaugural corporate-level assessment. This places the company in the **97th percentile**, among the **top 5% of all companies assessed globally across all industries**.

EcoVadis is one of the world's trusted providers of business sustainability ratings, assessing companies on environment, labour & human rights, ethics, and sustainable procurement. This recognition affirms Granules' robust sustainability practices and transparency in its business operations.

The company's **first-ever corporate-level submission to EcoVadis** builds on years of operational and environmental excellence across its manufacturing footprint. The rating reflects the company's purpose-driven transformation journey — *Healing lives responsibly through pioneering green science* — and aligns with its broader sustainability goals, including science-based climate targets, greener chemistry platforms, and safer workplace practices.

"This Gold rating is more than a recognition — it's a reminder that we are choosing to grow differently by placing sustainability at the heart of our progress," said **Dr. Krishna Prasad Chigurupati**, Chairman and Managing Director of Granules India. "It is a moment of pride, but also one of responsibility to continue raising the bar as we build a more resilient and responsible future."

**Priyanka Chigurupati**, Executive Director, added: "We deeply value the trust and partnership of our customers and suppliers. This milestone is a shared win — a testament to what's possible when we act together with 'One Planet, One Purpose'."

#### **About Granules India Ltd. (BSE: 532482, NSE: GRANULES)**

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. Granules is among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). Granules products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US, and UK. The Company has 10 manufacturing facilities out of which 8 are in India and 2 in the USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.

**Media Contact:**

Priyanka Chawla  
Manager- Corporate Communications  
[priyanka.chawla@granulesindia.com](mailto:priyanka.chawla@granulesindia.com)

**Investors Contact:**

**Chaitanya Tummala**  
Company Secretary  
[investorrelations@granulesindia.com](mailto:investorrelations@granulesindia.com)